Vesteck, Inc., a West Chester, Pa.-based early-stage medical device company, closed a $5.95M Series A financing, which included conversion of all existing convertible notes.
The round was led by Florida based New World Angels, followed by DeepWork Capital and Ocean Azul Partners.
The company intends to use the funds for the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to its clinical study for FDA clearance.
Led by CEO Joe Rafferty and Chief Medical Officer Dr. David H. Deaton, Vesteck is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets. Vesteck has designed a platform comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients. Their first product, the “Suture-Tight” nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.
FinSMEs
05/01/2022